Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Increase in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 6,000,000 shares, an increase of 6.0% from the December 31st total of 5,660,000 shares. Based on an average daily volume of 250,800 shares, the short-interest ratio is presently 23.9 days. Approximately 31.2% of the company’s stock are sold short.

Analysts Set New Price Targets

Several research firms have recently weighed in on DNTH. Oppenheimer increased their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $46.43.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Quest Partners LLC boosted its stake in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after buying an additional 1,124 shares during the period. R Squared Ltd purchased a new position in shares of Dianthus Therapeutics during the 4th quarter worth about $26,000. KBC Group NV bought a new position in Dianthus Therapeutics during the 4th quarter valued at about $35,000. SG Americas Securities LLC raised its holdings in shares of Dianthus Therapeutics by 104.0% in the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after buying an additional 4,506 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Dianthus Therapeutics during the second quarter worth $236,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Up 1.7 %

DNTH opened at $22.15 on Monday. Dianthus Therapeutics has a 52 week low of $18.00 and a 52 week high of $33.77. The firm has a 50-day simple moving average of $23.12 and a two-hundred day simple moving average of $25.94. The company has a market capitalization of $655.64 million, a PE ratio of -8.86 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, sell-side analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.